Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

PEG-interferon lambda 1 conjugates

A conjugate and interferon technology, applied in the direction of interferon, cytokine/lymphokine/interferon, drug combination, etc., can solve the problems of inconvenient treatment, expensive, short half-life, etc.

Inactive Publication Date: 2013-07-31
NANOGEN PHARMA BIOTECH CO LTD
View PDF20 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, because they typically have a short half-life, biologics need to be administered frequently to patients in order to maintain therapeutic serum or plasma levels of the drug
Injections that cannot be self-administered require frequent visits to clinics and trained medical personnel, making the treatment inconvenient and expensive

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • PEG-interferon lambda 1 conjugates
  • PEG-interferon lambda 1 conjugates
  • PEG-interferon lambda 1 conjugates

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0072] Example 1: Method for preparing an Escherichia coli strain comprising a gene encoding human recombinant interferon λ1 (IFNλ1)

[0073] The gene encoding IFNλ1 was artificially synthesized based on protein sequence data available from NCBI or other databases. The new method presented here reduces the time required to isolate genes but still provides results as accurate as conventional methods. The nucleic acid sequence for producing IFNλ1 in Nanogen Pharmaceutical Biotechnology Co., Ltd. is as follows figure 1 The amino acid sequence of the protein is shown as figure 2 shown.

[0074] The expression vector pNanogen IL29 (including T7 transcriptional promoter region, IFNλ1 transgene, T7 reverse promoter site, T7 transcriptional terminator, f1 promoter (origin), kanamycin resistance gene and replicated pUC promoter) is specially designed to The protein can be highly expressed to promote the fermentation of a large amount of IFNλ1 industrial production. image 3 , Fi...

Embodiment 2

[0076] Embodiment 2: the method for Escherichia coli fermentation production human recombinant IFNλ1

[0077] The fermentation process is carried out in a 140L fermenter with nutrient medium at a temperature of 37±0.5°C and an air pressure of 0.5m 3 / h, the pH is 7.0±0.2, the stirring rate is 300rpm, and by adding H 3 PO 4 or NH 4 OH keeps the pH between 6.8-7.2. After 8 hours (E. coli is in the logarithmic phase growth is the most effective time for cell growth), the temperature was cooled to 30±0.5°C, and the stirring speed was reduced to 200rpm to start the process of IFNλ1 production. The fermentation process was stopped after 4 hours and the cooled product was centrifuged at 6000 rpm to obtain biomass.

[0078]Biomass was disrupted in cell lysate (12 mL solution per 1 g wet biomass) by homogenization in a homogenization apparatus. The temperature was maintained at 4°C for 1 hour, and then the cells were disrupted 2 times by an ultrasonic device. The resulting suspen...

Embodiment 3

[0082] Example 3: Purification process of human recombinant IFNλ1

[0083] IFNλ1 was refolded by dissolving inclusion bodies in a refolding solution (25 mM Tris buffer, 1 mM EDTA, 1.2 M guanidine, pH 8.2) so that the final concentration of inclusion bodies was 500 μg / mL. The mixture was then kept at 2-8 °C for 16-24 h. The resulting mixture was subjected to a purification step on a Sephadex G25 column after desalting. The salt exchange buffer was phosphate buffer (10 mM, pH 8.0), and in step "Cation 1", the desalted mixture was loaded onto a Sephadex G25 column (the column was prepacked with CM-Sepharose FF gel and incubated at pH 8.0 Equilibrated in 10 mM phosphate buffer), use 10 mM sodium phosphate + 0.5 M NaCl (pH 8.0) to elute the product. The resulting protein solution was desalted and chromatographed as above (step "Cation 2"). The protein solution was then filtered through a gel column to obtain the product human recombinant IFNλ1 with a purity greater than 95% (see...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
weightaaaaaaaaaa
Login to View More

Abstract

The present application discloses novel PEG-interferon lambda 1 conjugates (PEG-1FN[lambda]1), preparation method thereof, pharmaceutical compositions containing these conjugates and processes for making the same. These conjugates have increased blood half-lives and persistence time compared to 1FN[lambda]1 and are effective in the treatment of hepatitis B and hepatitis C.

Description

[0001] Related applications: [0002] This application claims the benefit of Vietnamese Patent Application Serial No. VN1-2011-02222 filed on August 25, 2011, which is incorporated herein by reference. technical field [0003] In one embodiment, the present application discloses PEGylated derivatives of recombinant human interferon λ1 (PEG-interferon λ1 conjugates or PEG-IFNλ1), their preparation methods, pharmaceutical compositions containing these conjugates and methods for preparing them. method. Background technique [0004] Hepatitis C virus (HCV) is a major health problem and the leading cause of chronic liver disease worldwide. It is estimated that at least 180 million people worldwide are chronically infected with HCV. In Vietnam, the proportion of individuals infected with HCV in the population is 4%-9%, about 55%-85% of acutely infected HCV individuals will convert to chronic infection, and 5%-25% of these chronic carriers have 30% of people with liver cirrhosis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12P21/04C07K11/00
CPCC07K11/00C07K14/555A61K47/48215A61K38/21A61K47/60A61P1/16A61P31/12A61P31/14A61P31/20A61P35/00
Inventor 何南
Owner NANOGEN PHARMA BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com